Standout Papers

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with... 2021 2026 2022 2024152
  1. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial (2021)
    Bradley J. Monk, Nicoletta Colombo et al. The Lancet Oncology

Immediate Impact

1 from Science/Nature 38 standout
Sub-graph 1 of 15

Citing Papers

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
2025 Standout
Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy
2025 Standout
2 intermediate papers

Works of Carlos Linn being referenced

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Carlos Linn 85 192 26 94 91 14 268
Soizick Mesnage 41 164 35 122 99 9 254
Alisia Cesta 58 189 52 98 60 20 330
Shyam Aggarwal 53 142 32 72 52 19 262
Luisa Sánchez‐Lorenzo 37 184 20 57 43 17 269
Ahmed Kamel 46 108 24 122 46 13 276
Mei Cao 69 153 27 37 117 15 305
Lorenzo Alonso-Carrión 27 96 32 42 103 12 286
K.S. Grzankowski 17 102 27 67 111 17 235
Maria Kfoury 58 218 19 21 129 22 281
Lily Xu 28 169 33 30 162 12 322

All Works

Loading papers...

Rankless by CCL
2026